Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
Novo Nordisk backs view of 2020 sales growth of 3-6% at CER » 06:40
08/06/20
08/06
06:40
08/06/20
06:40
NVO

Novo Nordisk

$65.09 /

+0.46 (+0.71%)

For the 2020 outlook,…

For the 2020 outlook, sales growth is still expected to be 3-6% at CER, and operating profit growth is now expected to be 2-5% at CER, Novo Nordisk said.

ShowHide Related Items >><<
NVO Novo Nordisk
$65.09 /

+0.46 (+0.71%)

NVO Novo Nordisk
$65.09 /

+0.46 (+0.71%)

08/03/20 Morgan Stanley
Novo Nordisk price target lowered to DKK 425 from DKK 435 at Morgan Stanley
07/06/20 BofA
Novo Nordisk downgraded to Neutral from Buy at BofA
06/05/20 JPMorgan
JPMorgan backs Overweight on Novo Nordisk after STEP data
05/18/20 Morgan Stanley
Novo Nordisk price target raised to DKK 435 from DKK 425 at Morgan Stanley
NVO Novo Nordisk
$65.09 /

+0.46 (+0.71%)

NVO Novo Nordisk
$65.09 /

+0.46 (+0.71%)

NVO Novo Nordisk
$65.09 /

+0.46 (+0.71%)

NVO Novo Nordisk
$65.09 /

+0.46 (+0.71%)

Earnings
Novo Nordisk reports 1H operating profit up 9% in Danish kroner » 06:39
08/06/20
08/06
06:39
08/06/20
06:39
NVO

Novo Nordisk

$65.09 /

+0.46 (+0.71%)

Novo Nordisk reports…

Novo Nordisk reports operating profit increased by 9% in Danish kroner and by 8% at constant exchange rates in the first six months of 2020, as sales increased by 8% in Danish kroner and by 7% at CER to DKK 63.9B. Sales growth was positively impacted by COVID-19-related stocking, largely offset by fewer patients initiating treatment, the company said. Lars Fruergaard Jorgensen, president and CEO, said: "Despite COVID-19, we are satisfied by the performance in the first half of 2020 and by the progress made on our strategic aspirations. We saw a strong uptake of our GLP-1 portfolio and we continue to increase our diabetes value market share. Within R&D, the obesity clinical trial results are very encouraging. As COVID-19 continues to severely impact societies around the world, our priorities continue to be to safeguard our employees, continue supply of our life-saving medicines and help societies around the world to fight the pandemic."

ShowHide Related Items >><<
NVO Novo Nordisk
$65.09 /

+0.46 (+0.71%)

NVO Novo Nordisk
$65.09 /

+0.46 (+0.71%)

08/03/20 Morgan Stanley
Novo Nordisk price target lowered to DKK 425 from DKK 435 at Morgan Stanley
07/06/20 BofA
Novo Nordisk downgraded to Neutral from Buy at BofA
06/05/20 JPMorgan
JPMorgan backs Overweight on Novo Nordisk after STEP data
05/18/20 Morgan Stanley
Novo Nordisk price target raised to DKK 435 from DKK 425 at Morgan Stanley
NVO Novo Nordisk
$65.09 /

+0.46 (+0.71%)

NVO Novo Nordisk
$65.09 /

+0.46 (+0.71%)

NVO Novo Nordisk
$65.09 /

+0.46 (+0.71%)

NVO Novo Nordisk
$65.09 /

+0.46 (+0.71%)

Over a week ago
Recommendations
Novo Nordisk price target lowered to DKK 425 from DKK 435 at Morgan Stanley » 12:02
08/03/20
08/03
12:02
08/03/20
12:02
NVO

Novo Nordisk

$65.81 /

+0.51 (+0.78%)

Morgan Stanley analyst…

Morgan Stanley analyst Mark Purcell lowered the firm's price target on Novo Nordisk to DKK 425 from DKK 435 and keeps an Equal Weight rating on the shares.

ShowHide Related Items >><<
NVO Novo Nordisk
$65.81 /

+0.51 (+0.78%)

NVO Novo Nordisk
$65.81 /

+0.51 (+0.78%)

07/06/20 BofA
Novo Nordisk downgraded to Neutral from Buy at BofA
06/05/20 JPMorgan
JPMorgan backs Overweight on Novo Nordisk after STEP data
05/18/20 Morgan Stanley
Novo Nordisk price target raised to DKK 435 from DKK 425 at Morgan Stanley
05/13/20 JPMorgan
Novo Nordisk price target raised to DKK 480 from DKK 460 at JPMorgan
NVO Novo Nordisk
$65.81 /

+0.51 (+0.78%)

NVO Novo Nordisk
$65.81 /

+0.51 (+0.78%)

NVO Novo Nordisk
$65.81 /

+0.51 (+0.78%)

NVO Novo Nordisk
$65.81 /

+0.51 (+0.78%)

Options
Novo Nordisk call volume above normal and directionally bullish » 14:45
07/17/20
07/17
14:45
07/17/20
14:45
NVO

Novo Nordisk

$67.19 /

+1.57 (+2.39%)

Bullish option flow…

Bullish option flow detected in Novo Nordisk with 4,694 calls trading, 2x expected, and implied vol increasing over 2 points to 30.86%. Aug-20 72.5 calls and Sep-20 67.5 calls are the most active options, with total volume in those strikes near 4,300 contracts. The Put/Call Ratio is 0.02. Earnings are expected on August 6th.

ShowHide Related Items >><<
NVO Novo Nordisk
$67.19 /

+1.57 (+2.39%)

NVO Novo Nordisk
$67.19 /

+1.57 (+2.39%)

07/06/20 BofA
Novo Nordisk downgraded to Neutral from Buy at BofA
06/05/20 JPMorgan
JPMorgan backs Overweight on Novo Nordisk after STEP data
05/18/20 Morgan Stanley
Novo Nordisk price target raised to DKK 435 from DKK 425 at Morgan Stanley
05/13/20 JPMorgan
Novo Nordisk price target raised to DKK 480 from DKK 460 at JPMorgan
NVO Novo Nordisk
$67.19 /

+1.57 (+2.39%)

NVO Novo Nordisk
$67.19 /

+1.57 (+2.39%)

NVO Novo Nordisk
$67.19 /

+1.57 (+2.39%)

Conference/Events
International Society on Thrombosis & Haemostasis to hold a virtual event » 08:34
07/14/20
07/14
08:34
07/14/20
08:34
BAYRY

Bayer

$0.00 /

+ (+0.00%)

, BMRN

BioMarin

$124.59 /

-1.47 (-1.17%)

, BMY

Bristol-Myers

$57.76 /

+0.325 (+0.57%)

, CAH

Cardinal Health

$49.85 /

+0.49 (+0.99%)

, HAE

Haemonetics

$87.92 /

-0.215 (-0.24%)

, NVO

Novo Nordisk

$65.18 /

-0.23 (-0.35%)

, PFE

Pfizer

$35.22 /

+1.38 (+4.08%)

, PTLA

Portola Pharmaceuticals

$18.01 /

+ (+0.00%)

, QURE

uniQure

$44.09 /

-2.33 (-5.02%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, SMMNY

Siemens Healthineers

$0.00 /

+ (+0.00%)

, SNY

Sanofi

$50.96 /

+0.64 (+1.27%)

, TAK

Takeda Pharmaceutical

$17.10 /

-0.16 (-0.93%)

ISTH Congress 2020…

ISTH Congress 2020 Virtual Event will be held on July 12-14. Webcast Link

ShowHide Related Items >><<
TAK Takeda Pharmaceutical
$17.10 /

-0.16 (-0.93%)

SNY Sanofi
$50.96 /

+0.64 (+1.27%)

RHHBY Roche
$0.00 /

+ (+0.00%)

QURE uniQure
$44.09 /

-2.33 (-5.02%)

PTLA Portola Pharmaceuticals
$18.01 /

+ (+0.00%)

PFE Pfizer
$35.22 /

+1.38 (+4.08%)

NVO Novo Nordisk
$65.18 /

-0.23 (-0.35%)

HAE Haemonetics
$87.92 /

-0.215 (-0.24%)

CAH Cardinal Health
$49.85 /

+0.49 (+0.99%)

BMY Bristol-Myers
$57.76 /

+0.325 (+0.57%)

BMRN BioMarin
$124.59 /

-1.47 (-1.17%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

06/26/20 JPMorgan
Bayer price target raised to EUR 77 from EUR 75 at JPMorgan
06/26/20 Deutsche Bank
Bayer price target raised to EUR 87 from EUR 85 at Deutsche Bank
06/25/20 Morgan Stanley
Bayer price target raised to EUR 88 from EUR 83 at Morgan Stanley
06/25/20 HSBC
HSBC upgrades Bayer to Buy after settlement on most Monsanto cases in U.S.
BMRN BioMarin
$124.59 /

-1.47 (-1.17%)

07/08/20 Morgan Stanley
Morgan Stanley cuts BioMarin to Equal Weight with pipeline seen better priced in
07/08/20 Morgan Stanley
BioMarin downgraded to Equal Weight from Overweight at Morgan Stanley
07/06/20 Citi
BioMarin price target raised to $148 from $105 at Citi
06/19/20 Barclays
Barclays upgrades Swedish Orphan to Equal Weight on favorable trends
BMY Bristol-Myers
$57.76 /

+0.325 (+0.57%)

06/22/20 Morgan Stanley
Morgan Stanley sees Eliquis patent being upheld, ruling being 'imminent'
06/08/20 Bernstein
Gilead, AstraZeneca merger would make sense on economic basis, says Bernstein
06/02/20 Credit Suisse
Arena Pharmaceuticals price target raised to $87 from $77 at Credit Suisse
06/02/20 Cantor Fitzgerald
Arena Pharmaceuticals price target raised to $88 from $68 at Cantor Fitzgerald
CAH Cardinal Health
$49.85 /

+0.49 (+0.99%)

06/15/20 Morgan Stanley
Morgan Stanley upgrades AmerisourceBergen on opioid settlement potential
05/22/20 Wolfe Research
McKesson upgraded to Outperform from Peer Perform at Wolfe Research
05/15/20 UBS
McKesson, Cardinal Health upgraded to Buy from Neutral at UBS
05/15/20 UBS
Cardinal Health upgraded to Buy from Neutral at UBS
HAE Haemonetics
$87.92 /

-0.215 (-0.24%)

07/01/20 Raymond James
Haemonetics price target lowered to $113 from $125 at Raymond James
05/06/20 Barrington
Haemonetics downgraded to Market Perform from Outperform at Barrington
04/07/20 Raymond James
Haemonetics price target lowered to $130 from $150 at Raymond James
03/20/20 Jefferies
Haemonetics 'key strategic provider' for plasma COVID approaches, says Jefferies
NVO Novo Nordisk
$65.18 /

-0.23 (-0.35%)

07/06/20 BofA
Novo Nordisk downgraded to Neutral from Buy at BofA
06/05/20 JPMorgan
JPMorgan backs Overweight on Novo Nordisk after STEP data
05/18/20 Morgan Stanley
Novo Nordisk price target raised to DKK 435 from DKK 425 at Morgan Stanley
05/13/20 JPMorgan
Novo Nordisk price target raised to DKK 480 from DKK 460 at JPMorgan
PFE Pfizer
$35.22 /

+1.38 (+4.08%)

07/13/20 Canaccord
BioNTech price target raised to $75 from $60 at Canaccord
07/08/20 Piper Sandler
Opko Health price target raised to $6 from $4 at Piper Sandler
07/08/20 Argus
Pfizer positioned for stronger revenue growth in 2021 and beyond, says Argus
07/07/20 Needham
Vaxcyte initiated with a Buy at Needham
PTLA Portola Pharmaceuticals
$18.01 /

+ (+0.00%)

05/07/20 Stifel
Portola deal highlights value of PhaseBio's PB2452, says Stifel
05/06/20 B. Riley FBR
B. Riley boosts CytoSorbents target, says Portola deal highlights value
05/05/20 Citi
Portola Pharmaceuticals downgraded to Neutral from Buy at Citi
05/05/20 Jefferies
Jefferies sees Portola acquisition as neutral for Alexion
QURE uniQure
$44.09 /

-2.33 (-5.02%)

06/25/20
Fly Intel: Top five analyst downgrades
06/25/20 Guggenheim
uniQure HemB deal 'not the M&A some investors were hoping for,' says Guggenheim
06/25/20 H.C. Wainwright
uniQure price target lowered to $64 from $73 at H.C. Wainwright
06/25/20 Stifel
uniQure price target lowered to $78 from $86 at Stifel
RHHBY Roche
$0.00 /

+ (+0.00%)

07/13/20 Bernstein
Roche initiated with an Outperform at Bernstein
07/03/20 AlphaValue
Roche upgraded to Add from Reduce at AlphaValue
06/29/20 Piper Sandler
Herceptin/Perjecta approval another win for Halozyme, says Piper
06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
SMMNY Siemens Healthineers
$0.00 /

+ (+0.00%)

07/02/20 JPMorgan
Siemens Healthineers price target lowered to EUR 37.60 at JPMorgan
06/08/20 Citi
Siemens Healthineers upgraded to Buy from Neutral at Citi
06/05/20 Exane BNP Paribas
Siemens Healthineers downgraded to Neutral from Outperform at Exane BNP Paribas
05/26/20 Berenberg
Siemens Healthineers price target raised to EUR 52 from EUR 40 at Berenberg
SNY Sanofi
$50.96 /

+0.64 (+1.27%)

07/08/20 Piper Sandler
Piper upgrades Kiadis on 'platform validating' Sanofi deal
07/01/20 Roth Capital
Applied Genetic may attract Sanofi takeover interest, says Roth Capital
06/26/20 Truist
Translate Bio initiated with a Buy at SunTrust
TAK Takeda Pharmaceutical
$17.10 /

-0.16 (-0.93%)

06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
06/17/20 Oppenheimer
Takeda deal expands Neurocrine's pipeline into psychiatry, says Oppenheimer
04/20/20 SVB Leerink
Ascendis Pharma price target raised to $170 from $152 at SVB Leerink
03/25/20 Piper Sandler
Piper Sandler backs Overweight on 'well capitalized' Exelixis
SNY Sanofi
$50.96 /

+0.64 (+1.27%)

RHHBY Roche
$0.00 /

+ (+0.00%)

QURE uniQure
$44.09 /

-2.33 (-5.02%)

PTLA Portola Pharmaceuticals
$18.01 /

+ (+0.00%)

PFE Pfizer
$35.22 /

+1.38 (+4.08%)

NVO Novo Nordisk
$65.18 /

-0.23 (-0.35%)

HAE Haemonetics
$87.92 /

-0.215 (-0.24%)

CAH Cardinal Health
$49.85 /

+0.49 (+0.99%)

BMY Bristol-Myers
$57.76 /

+0.325 (+0.57%)

BMRN BioMarin
$124.59 /

-1.47 (-1.17%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

  • 06
    Sep
  • 14
    Aug
TAK Takeda Pharmaceutical
$17.10 /

-0.16 (-0.93%)

SNY Sanofi
$50.96 /

+0.64 (+1.27%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$35.22 /

+1.38 (+4.08%)

NVO Novo Nordisk
$65.18 /

-0.23 (-0.35%)

CAH Cardinal Health
$49.85 /

+0.49 (+0.99%)

BMY Bristol-Myers
$57.76 /

+0.325 (+0.57%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

SNY Sanofi
$50.96 /

+0.64 (+1.27%)

RHHBY Roche
$0.00 /

+ (+0.00%)

QURE uniQure
$44.09 /

-2.33 (-5.02%)

PTLA Portola Pharmaceuticals
$18.01 /

+ (+0.00%)

PFE Pfizer
$35.22 /

+1.38 (+4.08%)

NVO Novo Nordisk
$65.18 /

-0.23 (-0.35%)

CAH Cardinal Health
$49.85 /

+0.49 (+0.99%)

BMY Bristol-Myers
$57.76 /

+0.325 (+0.57%)

BMRN BioMarin
$124.59 /

-1.47 (-1.17%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

TAK Takeda Pharmaceutical
$17.10 /

-0.16 (-0.93%)

SNY Sanofi
$50.96 /

+0.64 (+1.27%)

QURE uniQure
$44.09 /

-2.33 (-5.02%)

PTLA Portola Pharmaceuticals
$18.01 /

+ (+0.00%)

PFE Pfizer
$35.22 /

+1.38 (+4.08%)

CAH Cardinal Health
$49.85 /

+0.49 (+0.99%)

BMY Bristol-Myers
$57.76 /

+0.325 (+0.57%)

BMRN BioMarin
$124.59 /

-1.47 (-1.17%)

Over a month ago
Hot Stocks
Pfizer pledges $100M to new Antimicrobial Resistance Action Fund » 15:23
07/09/20
07/09
15:23
07/09/20
15:23
PFE

Pfizer

$33.57 /

-0.19 (-0.56%)

, AMGN

Amgen

$252.34 /

+0.74 (+0.29%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, LLY

Eli Lilly

$166.59 /

-2.52 (-1.49%)

, GSK

GlaxoSmithKline

$40.37 /

-0.35 (-0.86%)

, MRK

Merck

$76.99 /

-0.88 (-1.13%)

, MKGAY

Merck KGaA

$0.00 /

+ (+0.00%)

, TEVA

Teva

$11.60 /

+0.21 (+1.84%)

, TAK

Takeda Pharmaceutical

$17.36 /

-0.135 (-0.77%)

, NVO

Novo Nordisk

$65.63 /

-0.23 (-0.35%)

, JNJ

Johnson & Johnson

$143.03 /

-0.21 (-0.15%)

, NVS

Novartis

$87.53 /

-0.585 (-0.66%)

Pfizer (PFE) announced…

Pfizer (PFE) announced earlier it has pledged $100M to the new Antimicrobial Resistance, or "AMR," Action Fund, which launched today, to help address the significant global public health need for new antibiotics due to the rapid rise of antibiotic-resistant infections. "The AMR Action Fund is a ground-breaking collaboration among more than 20 biopharmaceutical companies that aims to bring 2-4 new antibiotics to patients by 2030 through collaboration between pharmaceutical companies, philanthropies, development banks, and multilateral organizations to re-invigorate and accelerate antibiotic development," the company stated. "As the COVID-19 pandemic has shown, we must invest in the development of medicines now so that we are prepared to help prevent the next public health crisis," added Pfizer Chairman and CEO Albert Bourla. Other investors in the AMR Action Fund include Amgen (AMGN), Bayer (BAYRY), Roche (RHHBY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Merck (MRK), Merck KGaA (MKGAY), Teva (TEVA), Takeda Pharmaceutical (TAK), Novo Nordisk (NVO), Johnson & Johnson (JNJ) and Novartis (NVS). Reference Link

ShowHide Related Items >><<
TEVA Teva
$11.60 /

+0.21 (+1.84%)

TAK Takeda Pharmaceutical
$17.36 /

-0.135 (-0.77%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$33.57 /

-0.19 (-0.56%)

NVS Novartis
$87.53 /

-0.585 (-0.66%)

NVO Novo Nordisk
$65.63 /

-0.23 (-0.35%)

MRK Merck
$76.99 /

-0.88 (-1.13%)

MKGAY Merck KGaA
$0.00 /

+ (+0.00%)

LLY Eli Lilly
$166.59 /

-2.52 (-1.49%)

JNJ Johnson & Johnson
$143.03 /

-0.21 (-0.15%)

GSK GlaxoSmithKline
$40.37 /

-0.35 (-0.86%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AMGN Amgen
$252.34 /

+0.74 (+0.29%)

PFE Pfizer
$33.57 /

-0.19 (-0.56%)

07/08/20 Piper Sandler
Opko Health price target raised to $6 from $4 at Piper Sandler
07/08/20 Argus
Pfizer positioned for stronger revenue growth in 2021 and beyond, says Argus
07/07/20 Needham
Vaxcyte initiated with a Buy at Needham
07/02/20 B. Riley FBR
Novavax should be bought on weakness from Pfizer data, says B. Riley FBR
AMGN Amgen
$252.34 /

+0.74 (+0.29%)

07/02/20 Citi
Citi sees 'considerable amount of investor interest' coming back to Amgen
07/01/20 Piper Sandler
Amgen appeal rules in favor of patent validity, says Piper Sandler
07/01/20 Mizuho
Amgen patent win worth $5-$12 per share, says Mizuho
07/01/20 Goldman Sachs
Court ruling removes overhang for Amgen, says Goldman Sachs
BAYRY Bayer
$0.00 /

+ (+0.00%)

06/26/20 JPMorgan
Bayer price target raised to EUR 77 from EUR 75 at JPMorgan
06/26/20 Deutsche Bank
Bayer price target raised to EUR 87 from EUR 85 at Deutsche Bank
06/25/20 Morgan Stanley
Bayer price target raised to EUR 88 from EUR 83 at Morgan Stanley
06/25/20 HSBC
HSBC upgrades Bayer to Buy after settlement on most Monsanto cases in U.S.
RHHBY Roche
$0.00 /

+ (+0.00%)

07/03/20 AlphaValue
Roche upgraded to Add from Reduce at AlphaValue
06/29/20 Piper Sandler
Herceptin/Perjecta approval another win for Halozyme, says Piper
06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
06/10/20 Truist
Arcus Biosciences price target raised to $45 from $22 at SunTrust
LLY Eli Lilly
$166.59 /

-2.52 (-1.49%)

07/09/20 Morgan Stanley
Eli Lilly won't publish Phase 1 COVID antibody data, says Morgan Stanley
06/29/20 Mizuho
Eli Lilly price target raised to $164 from $155 at Mizuho
06/17/20 JPMorgan
Eli Lilly price target raised to $190 from $175 at JPMorgan
GSK GlaxoSmithKline
$40.37 /

-0.35 (-0.86%)

06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/19/20 Barclays
Glaxo belantamab AdCom a surprise, supports cautious view, says Barclays
06/16/20 Roth Capital
Ideaya Biosciences price target raised to $23 from $12 at Roth Capital
05/14/20 UBS
GlaxoSmithKline price target raised to 1,920 GBp from 1,900 GBp at UBS
MRK Merck
$76.99 /

-0.88 (-1.13%)

06/30/20 SVB Leerink
Seattle Genetics price target raised to $167 from $155 at SVB Leerink
06/30/20 Oppenheimer
Seattle Genetics price target raised to $210 from $200 at Oppenheimer
06/25/20 Lake Street
Lake Street says Keytruda approval improves outlook for Checkpoint's cosibelimab
MKGAY Merck KGaA
$0.00 /

+ (+0.00%)

05/15/20 Nord/LB
Merck KGaA downgraded to Hold from Buy at Nord/LB
03/06/20 UBS
UBS backs Neutral on Merck KGaA after Q4 results
12/02/19 Goldman Sachs
Merck KGaA reinstated with a Sell at Goldman Sachs
10/04/19 Loop Capital
Entegris price target raised to $51 from $47 at Loop Capital
TEVA Teva
$11.60 /

+0.21 (+1.84%)

07/02/20 Wells Fargo
Emergent BioSolutions price target raised to $93 from $85 at Wells Fargo
06/26/20 William Blair
Pfenex partner CHMP opinion 'material de-risking event,' says William Blair
06/17/20 Stifel
Amarin settlement with Apotex an 'incremental positive,' says Stifel
06/08/20 Guggenheim
Emergent BioSolutions price target lowered to $87 from $101 at Guggenheim
TAK Takeda Pharmaceutical
$17.36 /

-0.135 (-0.77%)

06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
06/17/20 Oppenheimer
Takeda deal expands Neurocrine's pipeline into psychiatry, says Oppenheimer
04/20/20 SVB Leerink
Ascendis Pharma price target raised to $170 from $152 at SVB Leerink
03/25/20 Piper Sandler
Piper Sandler backs Overweight on 'well capitalized' Exelixis
NVO Novo Nordisk
$65.63 /

-0.23 (-0.35%)

07/06/20 BofA
Novo Nordisk downgraded to Neutral from Buy at BofA
06/05/20 JPMorgan
JPMorgan backs Overweight on Novo Nordisk after STEP data
05/18/20 Morgan Stanley
Novo Nordisk price target raised to DKK 435 from DKK 425 at Morgan Stanley
05/13/20 JPMorgan
Novo Nordisk price target raised to DKK 480 from DKK 460 at JPMorgan
JNJ Johnson & Johnson
$143.03 /

-0.21 (-0.15%)

07/06/20 Baird
Cooper Companies downgraded to Neutral, Baird see confluence of issues
07/01/20 JMP Securities
Minerva's seltorexant still 'underappreciated' upside driver, says JMP
05/29/20 H.C. Wainwright
H.C. Wainwright sees path forward for Minerva's roluperidone despite setback
NVS Novartis
$87.53 /

-0.585 (-0.66%)

07/01/20 Jefferies
Amgen win on Enbrel patent removes key overhang, says Jefferies
07/01/20 Goldman Sachs
Global Blood Therapeutics upgraded to Buy from Neutral at Goldman Sachs
06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
TEVA Teva
$11.60 /

+0.21 (+1.84%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$33.57 /

-0.19 (-0.56%)

NVS Novartis
$87.53 /

-0.585 (-0.66%)

NVO Novo Nordisk
$65.63 /

-0.23 (-0.35%)

MRK Merck
$76.99 /

-0.88 (-1.13%)

LLY Eli Lilly
$166.59 /

-2.52 (-1.49%)

JNJ Johnson & Johnson
$143.03 /

-0.21 (-0.15%)

GSK GlaxoSmithKline
$40.37 /

-0.35 (-0.86%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AMGN Amgen
$252.34 /

+0.74 (+0.29%)

TEVA Teva
$11.60 /

+0.21 (+1.84%)

TAK Takeda Pharmaceutical
$17.36 /

-0.135 (-0.77%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$33.57 /

-0.19 (-0.56%)

NVO Novo Nordisk
$65.63 /

-0.23 (-0.35%)

MRK Merck
$76.99 /

-0.88 (-1.13%)

MKGAY Merck KGaA
$0.00 /

+ (+0.00%)

LLY Eli Lilly
$166.59 /

-2.52 (-1.49%)

JNJ Johnson & Johnson
$143.03 /

-0.21 (-0.15%)

GSK GlaxoSmithKline
$40.37 /

-0.35 (-0.86%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AMGN Amgen
$252.34 /

+0.74 (+0.29%)

TEVA Teva
$11.60 /

+0.21 (+1.84%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$33.57 /

-0.19 (-0.56%)

NVS Novartis
$87.53 /

-0.585 (-0.66%)

NVO Novo Nordisk
$65.63 /

-0.23 (-0.35%)

MRK Merck
$76.99 /

-0.88 (-1.13%)

LLY Eli Lilly
$166.59 /

-2.52 (-1.49%)

JNJ Johnson & Johnson
$143.03 /

-0.21 (-0.15%)

GSK GlaxoSmithKline
$40.37 /

-0.35 (-0.86%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AMGN Amgen
$252.34 /

+0.74 (+0.29%)

TEVA Teva
$11.60 /

+0.21 (+1.84%)

TAK Takeda Pharmaceutical
$17.36 /

-0.135 (-0.77%)

PFE Pfizer
$33.57 /

-0.19 (-0.56%)

NVS Novartis
$87.53 /

-0.585 (-0.66%)

MRK Merck
$76.99 /

-0.88 (-1.13%)

LLY Eli Lilly
$166.59 /

-2.52 (-1.49%)

JNJ Johnson & Johnson
$143.03 /

-0.21 (-0.15%)

GSK GlaxoSmithKline
$40.37 /

-0.35 (-0.86%)

AMGN Amgen
$252.34 /

+0.74 (+0.29%)

Downgrade
Novo Nordisk downgraded to Neutral from Buy at BofA » 05:59
07/06/20
07/06
05:59
07/06/20
05:59
NVO

Novo Nordisk

$66.36 /

+0.7 (+1.07%)

BofA analyst Sachin Jain…

BofA analyst Sachin Jain downgraded Novo Nordisk to Neutral from Buy.

ShowHide Related Items >><<
NVO Novo Nordisk
$66.36 /

+0.7 (+1.07%)

NVO Novo Nordisk
$66.36 /

+0.7 (+1.07%)

06/05/20 JPMorgan
JPMorgan backs Overweight on Novo Nordisk after STEP data
05/18/20 Morgan Stanley
Novo Nordisk price target raised to DKK 435 from DKK 425 at Morgan Stanley
05/13/20 JPMorgan
Novo Nordisk price target raised to DKK 480 from DKK 460 at JPMorgan
05/11/20
Fly Intel: Top five analyst downgrades
NVO Novo Nordisk
$66.36 /

+0.7 (+1.07%)

NVO Novo Nordisk
$66.36 /

+0.7 (+1.07%)

NVO Novo Nordisk
$66.36 /

+0.7 (+1.07%)

Hot Stocks
Intercept plunges, drags down some NASH peers after CRL from FDA » 07:26
06/29/20
06/29
07:26
06/29/20
07:26
ICPT

Intercept

$77.56 /

-2.09 (-2.62%)

, CBAY

CymaBay

$3.74 /

-0.11 (-2.86%)

, NGM

NGM Biopharmaceuticals

$22.37 /

-0.53 (-2.31%)

, MDGL

Madrigal Pharmaceuticals

$108.04 /

-2.46 (-2.23%)

, NVO

Novo Nordisk

$66.03 /

-1.18 (-1.76%)

, GNFT

Genfit

$5.57 /

-0.42 (-7.01%)

, LLY

Eli Lilly

$162.91 /

-0.09 (-0.06%)

, ALNY

Alnylam

$151.68 /

-4.765 (-3.05%)

Shares of Intercept…

Shares of Intercept Pharmaceuticals (ICPT) have plunged in early morning trading after the company announced that the U.S. Food and Drug Administration has issued a Complete Response Letter regarding the New Drug Application for obeticholic acid for the treatment of fibrosis due to nonalcoholic steatohepatitis, or NASH. Based on the data the FDA has reviewed to date, the Agency has determined that the predicted benefit of OCA based on a surrogate histopathologic endpoint remains uncertain and does not sufficiently outweigh the potential risks to support accelerated approval for the treatment of patients with liver fibrosis due to NASH, Intercept tells investors. Following the announcement, shares of Intercept are down $25.82, or 33%, to $51.67 in pre-market trading. A number of other companies working on NASH treatments are also moving lower, with CymaBay (CBAY) down about 3% and NGM Biopharmaceuticals (NGM) fractionally lower. Other companies exploring NASH treatments include Madrigal Pharmaceuticals (MDGL), Novo Nordisk (NVO), Genfit (GNFT), Eli Lilly (LLY), and Alnylam Pharmaceuticals (ALNY).

ShowHide Related Items >><<
NVO Novo Nordisk
$66.03 /

-1.18 (-1.76%)

NGM NGM Biopharmaceuticals
$22.37 /

-0.53 (-2.31%)

MDGL Madrigal Pharmaceuticals
$108.04 /

-2.46 (-2.23%)

LLY Eli Lilly
$162.91 /

-0.09 (-0.06%)

ICPT Intercept
$77.56 /

-2.09 (-2.62%)

GNFT Genfit
$5.57 /

-0.42 (-7.01%)

CBAY CymaBay
$3.74 /

-0.11 (-2.86%)

ALNY Alnylam
$151.68 /

-4.765 (-3.05%)

ICPT Intercept
$77.56 /

-2.09 (-2.62%)

06/25/20 H.C. Wainwright
Intercept initiated with a Neutral at H.C. Wainwright
06/04/20 BMO Capital
Intercept initiated with an Outperform at BMO Capital
05/22/20 B. Riley FBR
Intercept weakness on 'slight' delay should be bought, says B. Riley FBR
05/22/20 Raymond James
Intercept downgraded at Raymond James after OCA NDA is postponed
CBAY CymaBay
$3.74 /

-0.11 (-2.86%)

06/22/20 B. Riley FBR
CymaBay risk/reward favorable into FDA engagement, says B. Riley FBR
05/26/20 H.C. Wainwright
CymaBay upgraded to Buy from Neutral at H.C. Wainwright
05/15/20 Citi
CymaBay price target raised to $7 from $1.60 at Citi
05/12/20 B. Riley FBR
CymaBay upgraded to Buy from Neutral at B. Riley FBR
NGM NGM Biopharmaceuticals
$22.37 /

-0.53 (-2.31%)

06/04/20 BMO Capital
NGM Biopharmaceuticals initiated with an Outperform at BMO Capital
05/06/20 Stifel
Stifel says semaglutide data a 'slight positive' for NGM Biopharmaceuticals
04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
03/31/20 H.C. Wainwright
Akero's BALANCED study results 'quite impressive,' says H.C. Wainwright
MDGL Madrigal Pharmaceuticals
$108.04 /

-2.46 (-2.23%)

06/04/20 BMO Capital
Madrigal Pharmaceuticals initiated with a Market Perform at BMO Capital
05/22/20 B. Riley FBR
Madrigal Pharmaceuticals price target raised to $174 from $134 at B. Riley FBR
05/08/20 H.C. Wainwright
Madrigal Pharmaceuticals price target lowered to $168 from $215 at H.C. Wainwright
05/06/20 Goldman Sachs
Goldman says Novo Nordisk NASH data a 'clear positive' for Intercept
NVO Novo Nordisk
$66.03 /

-1.18 (-1.76%)

06/05/20 JPMorgan
JPMorgan backs Overweight on Novo Nordisk after STEP data
05/18/20 Morgan Stanley
Novo Nordisk price target raised to DKK 435 from DKK 425 at Morgan Stanley
05/13/20 JPMorgan
Novo Nordisk price target raised to DKK 480 from DKK 460 at JPMorgan
05/11/20
Fly Intel: Top five analyst downgrades
GNFT Genfit
$5.57 /

-0.42 (-7.01%)

06/25/20 BofA
Genfit's NASH program 'all but done,' says BofA, initiating with an Underperform
06/25/20 BofA
Genfit initiated with an Underperform at BofA
05/13/20 Bryan Garnier
Genfit downgraded to Neutral from Buy at Bryan Garnier
LLY Eli Lilly
$162.91 /

-0.09 (-0.06%)

06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
06/17/20 JPMorgan
Eli Lilly price target raised to $190 from $175 at JPMorgan
06/16/20
Fly Intel: Top five analyst upgrades
06/16/20 Guggenheim
Guggenheim upgrades Eli Lilly to Buy after 'transformational' breast cancer data
ALNY Alnylam
$151.68 /

-4.765 (-3.05%)

06/08/20 Cantor Fitzgerald
Alnylam lumasiran data reinforces confidence in efficacy, says Cantor Fitzgerald
06/07/20 Stifel
No surprises in 'positive' Alnylan Lumasiran ILLUMINATE-A data, says Stifel
05/12/20 RBC Capital
Alnylam initiated with a Sector Perform at RBC Capital
05/07/20 Oppenheimer
Alnylam price target raised to $162 from $140 at Oppenheimer
NVO Novo Nordisk
$66.03 /

-1.18 (-1.76%)

NGM NGM Biopharmaceuticals
$22.37 /

-0.53 (-2.31%)

MDGL Madrigal Pharmaceuticals
$108.04 /

-2.46 (-2.23%)

LLY Eli Lilly
$162.91 /

-0.09 (-0.06%)

ICPT Intercept
$77.56 /

-2.09 (-2.62%)

CBAY CymaBay
$3.74 /

-0.11 (-2.86%)

ALNY Alnylam
$151.68 /

-4.765 (-3.05%)

  • 11
    Dec
NVO Novo Nordisk
$66.03 /

-1.18 (-1.76%)

LLY Eli Lilly
$162.91 /

-0.09 (-0.06%)

GNFT Genfit
$5.57 /

-0.42 (-7.01%)

ALNY Alnylam
$151.68 /

-4.765 (-3.05%)

NVO Novo Nordisk
$66.03 /

-1.18 (-1.76%)

NGM NGM Biopharmaceuticals
$22.37 /

-0.53 (-2.31%)

LLY Eli Lilly
$162.91 /

-0.09 (-0.06%)

ICPT Intercept
$77.56 /

-2.09 (-2.62%)

CBAY CymaBay
$3.74 /

-0.11 (-2.86%)

NGM NGM Biopharmaceuticals
$22.37 /

-0.53 (-2.31%)

LLY Eli Lilly
$162.91 /

-0.09 (-0.06%)

CBAY CymaBay
$3.74 /

-0.11 (-2.86%)

Hot Stocks
Novo Nordisk reports Rybelsus approved in Japan for treatment of type 2 diabetes » 07:03
06/29/20
06/29
07:03
06/29/20
07:03
NVO

Novo Nordisk

$66.03 /

-1.18 (-1.76%)

, MRK

Merck

$75.16 /

-1.43 (-1.87%)

Novo Nordisk (NVO)…

Novo Nordisk (NVO) announced that the Japanese Ministry of Health, Labour and Welfare has approved Rybelsus, which it calls "the first and only oral glucagon-like peptide-1 receptor agonist in a tablet," for the treatment of adults with type 2 diabetes. Novo Nordisk will now initiate reimbursement negotiations and expects to launch Rybelsus in Japan thereafter. Novo Nordisk and Merck (MRK), known as MSD outside the United States and Canada, will be co-promoting Rybelsus in Japan.

ShowHide Related Items >><<
NVO Novo Nordisk
$66.03 /

-1.18 (-1.76%)

MRK Merck
$75.16 /

-1.43 (-1.87%)

NVO Novo Nordisk
$66.03 /

-1.18 (-1.76%)

06/05/20 JPMorgan
JPMorgan backs Overweight on Novo Nordisk after STEP data
05/18/20 Morgan Stanley
Novo Nordisk price target raised to DKK 435 from DKK 425 at Morgan Stanley
05/13/20 JPMorgan
Novo Nordisk price target raised to DKK 480 from DKK 460 at JPMorgan
05/11/20
Fly Intel: Top five analyst downgrades
MRK Merck
$75.16 /

-1.43 (-1.87%)

06/25/20 Lake Street
Lake Street says Keytruda approval improves outlook for Checkpoint's cosibelimab
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/23/20 Morgan Stanley
Merck's COVID-19 antiviral candidate underappreciated, says Morgan Stanley
06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
NVO Novo Nordisk
$66.03 /

-1.18 (-1.76%)

MRK Merck
$75.16 /

-1.43 (-1.87%)

NVO Novo Nordisk
$66.03 /

-1.18 (-1.76%)

MRK Merck
$75.16 /

-1.43 (-1.87%)

NVO Novo Nordisk
$66.03 /

-1.18 (-1.76%)

MRK Merck
$75.16 /

-1.43 (-1.87%)

MRK Merck
$75.16 /

-1.43 (-1.87%)

Conference/Events
Healthcare Financial Management Association to hold a virtual conference » 08:56
06/24/20
06/24
08:56
06/24/20
08:56
MTBC

MTBC

$8.50 /

-0.26 (-2.97%)

, NVZMY

Novozymes

$0.00 /

+ (+0.00%)

, NVS

Novartis

$90.49 /

-0.09 (-0.10%)

, NVAX

Novavax

$69.66 /

+3.72 (+5.64%)

, MRK

Merck

$77.11 /

+0.4 (+0.52%)

, LOGI

Logitech

$62.73 /

-0.32 (-0.51%)

, REGN

Regeneron

$628.72 /

+0.81 (+0.13%)

, RDY

Dr. Reddy's

$54.33 /

+1.04 (+1.95%)

, FREQ

Frequency Therapeutics

$22.68 /

-0.47 (-2.03%)

, RCKT

Rocket Pharmaceuticals

$22.80 /

+0.275 (+1.22%)

, TRVI

Trevi Therapeutics

$5.71 /

+0.26 (+4.77%)

, CSU

Capital Senior Living

$0.76 /

-0.037 (-4.64%)

, NVO

Novo Nordisk

$67.93 /

-0.005 (-0.01%)

HFMA 2020 Digital Annual…

HFMA 2020 Digital Annual Conference will be held on June 24. Webcast Link

ShowHide Related Items >><<
TRVI Trevi Therapeutics
$5.71 /

+0.26 (+4.77%)

REGN Regeneron
$628.72 /

+0.81 (+0.13%)

RDY Dr. Reddy's
$54.33 /

+1.04 (+1.95%)

RCKT Rocket Pharmaceuticals
$22.80 /

+0.275 (+1.22%)

NVS Novartis
$90.49 /

-0.09 (-0.10%)

NVO Novo Nordisk
$67.93 /

-0.005 (-0.01%)

NVAX Novavax
$69.66 /

+3.72 (+5.64%)

MTBC MTBC
$8.50 /

-0.26 (-2.97%)

MRK Merck
$77.11 /

+0.4 (+0.52%)

LOGI Logitech
$62.73 /

-0.32 (-0.51%)

FREQ Frequency Therapeutics
$22.68 /

-0.47 (-2.03%)

CSU Capital Senior Living
$0.76 /

-0.037 (-4.64%)

MTBC MTBC
$8.50 /

-0.26 (-2.97%)

06/22/20 H.C. Wainwright
MTBC upgraded to Buy from Neutral at H.C. Wainwright
06/02/20 Ladenburg
MTBC initiated with a Buy at Ladenburg
03/03/20
LD Micro to hold a virtual conference
03/02/20
Fly Intel: Top five analyst downgrades
NVZMY Novozymes
$0.00 /

+ (+0.00%)

05/12/20 Credit Suisse
Novozymes downgraded to Underperform from Outperform at Credit Suisse
04/01/20 Goldman Sachs
Novozymes downgraded to Sell from Buy at Goldman Sachs
03/13/20
Goldman Sachs to hold a conference
01/14/20 Exane BNP Paribas
Novozymes downgraded to Neutral from Outperform at Exane BNP Paribas
NVS Novartis
$90.49 /

-0.09 (-0.10%)

06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
06/16/20 Guggenheim
Guggenheim upgrades Alcon to Buy on strong momentum exiting shutdown
06/15/20
Fly Intel: Top five analyst upgrades
06/15/20 Citi
Novartis upgraded to Buy from Neutral at Citi
NVAX Novavax
$69.66 /

+3.72 (+5.64%)

06/19/20 Cantor Fitzgerald
Novavax price target raised to $88 from $45 at Cantor Fitzgerald
06/05/20
Fly Intel: Top five analyst upgrades
06/05/20 JPMorgan
JPMorgan upgrades Novavax to Neutral despite 'shaky fundamentals'
06/05/20 B. Riley FBR
Novavax price target raised to $74 from $61 at B. Riley FBR
MRK Merck
$77.11 /

+0.4 (+0.52%)

06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/23/20 Morgan Stanley
Merck's COVID-19 antiviral candidate underappreciated, says Morgan Stanley
06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
06/12/20 Wolfe Research
Merck downgraded to Peer Perform from Outperform at Wolfe Research
LOGI Logitech
$62.73 /

-0.32 (-0.51%)

06/24/20 Wedbush
Logitech downgraded to Neutral at Wedbush with limited multiple expansion ahead
06/24/20 Wedbush
Logitech downgraded to Neutral from Outperform at Wedbush
06/04/20 DA Davidson
Logitech price target raised to $70 from $64 at DA Davidson
05/21/20
Fly Intel: Top five analyst downgrades
REGN Regeneron
$628.72 /

+0.81 (+0.13%)

06/24/20 Credit Suisse
Regeneron price target raised to $700 from $605 at Credit Suisse
06/18/20 Piper Sandler
AbbVie atopic dermatitis data a postive, says Piper Sandler
06/15/20 Piper Sandler
Piper says 'meaningfully above-consensus estimates' for Dupixent are right
RDY Dr. Reddy's
$54.33 /

+1.04 (+1.95%)

06/17/20 SVB Leerink
Amarin doubling down on appeal after settlement with Apotex, says SVB Leerink
06/17/20 Stifel
Amarin settlement with Apotex an 'incremental positive,' says Stifel
04/21/20 Nomura Instinet
Dr. Reddy's price target raised to INR 4,426 from INR 3,684
03/31/20 Goldman Sachs
Goldman downgrades Amarin, cuts target to $4 from $27 after patent ruling
FREQ Frequency Therapeutics
$22.68 /

-0.47 (-2.03%)

05/18/20 JPMorgan
JPMorgan downgrades Frequency Therapeutics on unclear data timelines
05/18/20 JPMorgan
Frequency Therapeutics downgraded to Neutral from Overweight at JPMorgan
10/28/19 JPMorgan
Frequency Therapeutics initiated with an Overweight at JPMorgan
10/28/19 Cowen
Frequency Therapeutics initiated with an Outperform at Cowen
RCKT Rocket Pharmaceuticals
$22.80 /

+0.275 (+1.22%)

05/13/20 Piper Sandler
Rocket Pharmaceuticals programs look even more promising, says Piper Sandler
03/05/20 Piper Sandler
Piper sees 'substantial value' for Rocket from numerous trial readouts
12/09/19 Oppenheimer
Rocket Pharmaceuticals price target raised to $42 from $36 at Oppenheimer
12/06/19 Baird
Rocket Pharmaceuticals elevated to Fresh Pick, target raised to $41 at Baird
TRVI Trevi Therapeutics
$5.71 /

+0.26 (+4.77%)

CSU Capital Senior Living
$0.76 /

-0.037 (-4.64%)

09/03/19 Barclays
Capital Senior Living initiated with an Underweight at Barclays
NVO Novo Nordisk
$67.93 /

-0.005 (-0.01%)

06/05/20 JPMorgan
JPMorgan backs Overweight on Novo Nordisk after STEP data
05/18/20 Morgan Stanley
Novo Nordisk price target raised to DKK 435 from DKK 425 at Morgan Stanley
05/13/20 JPMorgan
Novo Nordisk price target raised to DKK 480 from DKK 460 at JPMorgan
05/11/20
Fly Intel: Top five analyst downgrades
TRVI Trevi Therapeutics
$5.71 /

+0.26 (+4.77%)

REGN Regeneron
$628.72 /

+0.81 (+0.13%)

RDY Dr. Reddy's
$54.33 /

+1.04 (+1.95%)

RCKT Rocket Pharmaceuticals
$22.80 /

+0.275 (+1.22%)

NVS Novartis
$90.49 /

-0.09 (-0.10%)

NVO Novo Nordisk
$67.93 /

-0.005 (-0.01%)

NVAX Novavax
$69.66 /

+3.72 (+5.64%)

MTBC MTBC
$8.50 /

-0.26 (-2.97%)

MRK Merck
$77.11 /

+0.4 (+0.52%)

LOGI Logitech
$62.73 /

-0.32 (-0.51%)

FREQ Frequency Therapeutics
$22.68 /

-0.47 (-2.03%)

CSU Capital Senior Living
$0.76 /

-0.037 (-4.64%)

REGN Regeneron
$628.72 /

+0.81 (+0.13%)

NVS Novartis
$90.49 /

-0.09 (-0.10%)

NVO Novo Nordisk
$67.93 /

-0.005 (-0.01%)

NVAX Novavax
$69.66 /

+3.72 (+5.64%)

MRK Merck
$77.11 /

+0.4 (+0.52%)

REGN Regeneron
$628.72 /

+0.81 (+0.13%)

RDY Dr. Reddy's
$54.33 /

+1.04 (+1.95%)

NVS Novartis
$90.49 /

-0.09 (-0.10%)

NVO Novo Nordisk
$67.93 /

-0.005 (-0.01%)

NVAX Novavax
$69.66 /

+3.72 (+5.64%)

MRK Merck
$77.11 /

+0.4 (+0.52%)

LOGI Logitech
$62.73 /

-0.32 (-0.51%)

REGN Regeneron
$628.72 /

+0.81 (+0.13%)

NVS Novartis
$90.49 /

-0.09 (-0.10%)

NVAX Novavax
$69.66 /

+3.72 (+5.64%)

MRK Merck
$77.11 /

+0.4 (+0.52%)

LOGI Logitech
$62.73 /

-0.32 (-0.51%)

FREQ Frequency Therapeutics
$22.68 /

-0.47 (-2.03%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.